Brentuximab vedotin
NL202100762
Phase 3 small_molecule active
Quick answer
Brentuximab vedotin for Diffuse Large B-cell-lymphoma is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Diffuse Large B-cell-lymphoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active